Elesclomol copper - Engrail Therapeutics
Alternative Names: ENX-103; ENX-203Latest Information Update: 17 Mar 2023
At a glance
- Originator Texas A&M University
- Developer Engrail Therapeutics
- Class Antineoplastics; Hydrazines; Ketones; Small molecules; Thiones
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Menkes kinky hair syndrome
Most Recent Events
- 17 Mar 2023 Preclinical trials in Menkes kinky hair syndrome in USA (unspecified route) (Engrail Therapeutics pipeline, March 2023)
- 17 Mar 2023 Pharmacodynamics data from preclinical trial in Menkes kinky hair syndrome released by Engrail Therapeutics, before March 2023 (Engrail Therapeutics pipeline, March 2023)
- 08 Sep 2021 Elesclomol licensed to Engrail Therapeutics worldwide